Jindi Han
Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
SMARCA4-deficient thoracic tumors exhibit an immunosuppressive microenvironment and respond to combined antiangiogenic and immune checkpoint inhibitor therapy.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 04, 2025
Treatment Efficacy, Chemoradiotherapy Benefits, and Survival Disparities by Histology in Primary Mediastinal Germ Cell Tumors: 15-Year Results of a Single-Center Cohort Study.
Journal: Asia-Pacific journal of clinical oncology
Published: April 01, 2025
Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China.
Journal: Frontiers in oncology
Published: February 16, 2025
Immune checkpoint inhibitor-related myocarditis in patients with lung cancer.
Journal: BMC cancer
Published: December 16, 2024
Nivolumab combined docetaxel versus nivolumab in patients with previously treated nonsmall cell lung cancer: a phase 2 study.
Journal: Anti-cancer drugs
Published: January 19, 2024
The overall survival benefit in Chinese ALK+ NSCLC patients received targeted therapies.
Journal: Journal of thoracic disease
Published: March 31, 2022
Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study.
Journal: Technology in cancer research & treatment
Published: November 25, 2021
Comparison of endostatin combined with PT-DC versus bevacizumab combined with PT-DC in the first-line treatment of advanced lung adenocarcinoma: a retrospective propensity score-matched cohort study.
Journal: Annals of palliative medicine
Published: May 10, 2021
Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC.
Journal: Cancer immunology, immunotherapy : CII
Published: December 28, 2020
Prognostic factor analysis of patients with small cell lung cancer: Real-world data from 988 patients.
Journal: Thoracic cancer
Published: November 27, 2020
Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China.
Journal: Frontiers in oncology
Published: September 17, 2020
A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer.
Journal: International journal of cancer
Published: March 21, 2020
Last Updated: 09/26/2026